PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för PD 0325901. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

15 hits

Bibliografisk träff 2015-05-14

MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.

Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.

Clin Cancer Res · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-14-3377

Bibliografisk träff 2015-04-22

Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.

Jousma E, Rizvi TA, Wu J, Janhofer D, Dombi E, Dunn RS, Kim MO, Masters AR, Jones DR, Cripe TP, Ratner N.

Pediatr Blood Cancer · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/pbc.25546

Bibliografisk träff 2015-02-23

MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.

Bian Y, Han J, Kannabiran V, Mohan S, Cheng H, Friedman J, Zhang L, VanWaes C, Chen Z.

Int J Biol Sci · research support, n.i.h., intramural; research-article; journal article · DOI 10.7150/ijbs.10745

Bibliografisk träff 2014-10-18

Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.

Paulo JA, McAllister FE, Everley RA, Beausoleil SA, Banks AS, Gygi SP.

Proteomics · research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/pmic.201400154

Bibliografisk träff 2014-07-01

A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.

El-Hoss J, Cheng T, Carpenter EC, Sullivan K, Deo N, Mikulec K, Little DG, Schindeler A.

J Bone Joint Surg Am · journal article · DOI 10.2106/jbjs.m.00862

Bibliografisk träff 2013-11-20

Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib).

El-Hoss J, Kolind M, Jackson MT, Deo N, Mikulec K, McDonald MM, Little CB, Little DG, Schindeler A.

Bone · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bone.2013.11.013

Bibliografisk träff 2012-07-02

Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.

Torti VR, Wojciechowicz D, Hu W, John-Baptiste A, Evering W, Troche G, Marroquin LD, Smeal T, Yamazaki S, Palmer CL, Burns-Naas LA, Bagrodia S.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-11-0984

Bibliografisk träff 2011-04-24

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.

Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-011-1620-1

Bibliografisk träff 2010-06-29

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.

Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-10-0062

Bibliografisk träff 2010-03-23

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.

Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM.

Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1158/1078-0432.ccr-09-1920

Bibliografisk träff 2010-03-09

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.

LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD.

Clin Cancer Res · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-09-1883

Bibliografisk träff 2009-12-01

PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.

Huang W, Yang AH, Matsumoto D, Collette W, Marroquin L, Ko M, Aguirre S, Younis HS.

J Ocul Pharmacol Ther · journal article · DOI 10.1089/jop.2009.0060

Bibliografisk träff 2008-10-15

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA, Smith Y, Warmus JS, Tecle H.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2008.10.054

Bibliografisk träff 2008-08-01

Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.

Liu D, Xing M.

Thyroid · research-article; journal article; research support, n.i.h., extramural · DOI 10.1089/thy.2007.0357

Bibliografisk träff 2006-08-31

Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration.

Brown AP, Carlson TC, Loi CM, Graziano MJ.

Cancer Chemother Pharmacol · journal article · DOI 10.1007/s00280-006-0323-5